logo
  • About Us
    • Company Overview
    • Vision / Mission / Values
    • Leadership
    • Clinical Advisory Board
    • Partnering
  • Our Approach
    • Technologies
    • Manufacturing
    • Publications
  • Pipeline
    • Pipeline
      • Autologous CAR-T
      • Allogeneic CAR-T
    • Expanded Access
  • Investors
    • Announcements
    • Corporate Governance
    • Corporate Deck & Presentations
      • Webcasts
      • Presentations
    • Financial Reports
    • Listing Documents
    • IR Contact
  • Newsroom
  • Careers
    • Join Us
  • Contact Us
EN 简
  • About Us
    • Company Overview
    • Vision / Mission / Values
    • Leadership
    • Clinical Advisory Board
    • Partnering
  • Our Approach
    • Technologies
    • Manufacturing
    • Publications
  • Pipeline
    • Pipeline
      • Autologous CAR-T
      • Allogeneic CAR-T
    • Expanded Access
  • Investors
    • Announcements
    • Corporate Governance
    • Corporate Deck & Presentations
      • Webcasts
      • Presentations
    • Financial Reports
    • Listing Documents
    • IR Contact
  • Newsroom
  • Careers
    • Join Us
  • Contact Us

Newsroom

  • Home -
  • Newsroom -
20
Oct 2025
CARsgen Presents Preliminary Results on Satri-cel for Adjuvant Therapy of Pancreatic Cancer at ESMO Congress 2025
Oct 20, 2025
19
Oct 2025
Case Report | Preliminary Clinical Data of CARsgen’s Allogeneic BCMA CAR-T Product CT0596 for the Treatment of Primary Plasma Cell Leukemia
Oct 19, 2025
13
Oct 2025
CARsgen Announces Premarket Approval Application of Claudin18.2 Companion Diagnostic Kit Accepted by China’s NMPA
Oct 13, 2025
08
Oct 2025
CARsgen Presents Results on GPRC5D CAR-T CT071 in The Lancet Haematology
Oct 08, 2025
06
Oct 2025
ASH Preview | CARsgen to Present Results on Allogeneic BCMA CAR-T CT0596 at ASH 2025 Annual Congress
Oct 06, 2025
24
Sep 2025
Passing Away of Non-Executive Director
Sep 24, 2025
18
Sep 2025
CARsgen Presents Updated Long-term Follow-up Results for Zevor-cel at IMS 2025
Sep 18, 2025
12
Sep 2025
Preliminary Clinical Data of Allogeneic CD19/CD20 CAR-T Product for Mantle Cell Lymphoma Reported at Academic Conference
Sep 12, 2025
15
Aug 2025
CARsgen Therapeutics Announces 2025 Interim Results
Aug 15, 2025
22
Jul 2025
ESMO Preview | CARsgen to Present Results on Satri-cel for Adjuvant Therapy of Pancreatic Cancer at ESMO Congress 2025
Jul 22, 2025
  • 1
  • 2
  • ...
  • 11
Wechat
qr
Linkedin
  • About Us
    • Company Overview
    • Vision / Mission / Values
    • Leadership
    • Clinical Advisory Board
    • Partnering
  • Our Approach
    • Technologies
    • Manufacturing
    • Publications
  • Pipeline
    • Pipeline
    • Expanded Access
  • Investors
    • Announcements
    • Corporate Governance
    • Corporate Deck & Presentations
    • Financial Reports
    • Listing Documents
    • IR Contact
  • Newsroom
  • Careers
    • Join Us
  • Contact Us
Privacy Policy Terms of Use Developed by Euroland IR
Copyright ©2021-2025 CARsgen Therapeutics Holdings Limited